These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25091378)

  • 1. A multicenter, open-label study of an intravenous short-acting β1-adrenergic receptor antagonist landiolol hydrochloride for coronary computed tomography angiography by 16-slice multi-detector computed tomography in Japanese patients with suspected ischemic cardiac disease.
    Hirano M; Yamashina A; Hara K; Ikari Y; Jinzaki M; Iino M; Yamaguchi T; Tanimoto M; Kuribayashi S;
    Drugs R D; 2014 Sep; 14(3):185-94. PubMed ID: 25091378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled, phase III study of the short-acting β1-adrenergic receptor blocker landiolol hydrochloride for coronary computed tomography angiography in Japanese patients with suspected ischemic cardiac disease.
    Hirano M; Yamashina A; Hara K; Ikari Y; Jinzaki M; Iino M; Yamaguchi T; Tanimoto M; Kuribayashi S;
    Clin Drug Investig; 2014 Jan; 34(1):53-62. PubMed ID: 24174275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-finding study of landiolol hydrochloride: a short-acting β1-blocker for controlling heart rate during coronary computed-tomography angiography in Japan.
    Hirano M; Hara K; Ikari Y; Jinzaki M; Iino M; Hamada C; Kuribayashi S
    Adv Ther; 2013 Sep; 30(9):803-18. PubMed ID: 24062147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a bolus injection of landiolol hydrochloride as a premedication for multidetector-row computed tomography coronary angiography.
    Osawa K; Miyoshi T; Sato S; Akagi N; Morimitsu Y; Nakamura K; Kohno K; Kusano K; Kanazawa S; Ito H
    Circ J; 2013; 77(1):146-52. PubMed ID: 23037522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease.
    Jinzaki M; Hirano M; Hara K; Suzuki T; Yamashina A; Ikari Y; Iino M; Yamaguchi T; Kuribayashi S
    Int J Cardiovasc Imaging; 2013 Jun; 29 Suppl 1(Suppl 1):7-20. PubMed ID: 23784548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation-Dose-Lowering Effects of Landiolol Hydrochloride in Coronary Angiography Using Computed Tomography (DELIGHT)　- A Prospective Multicenter Study.
    Kido T; Mochizuki T; Hirano M; Yamada Y; Tanaka R; Kanzaki S; Higashi M; Jinzaki M; Yoshioka K; Kuribayashi S
    Circ J; 2016 Apr; 80(5):1225-31. PubMed ID: 27019983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study.
    Taenaka N; Kikawa S
    Am J Cardiovasc Drugs; 2013 Oct; 13(5):353-64. PubMed ID: 23818039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: preliminary study.
    Hoshi T; Sato A; Nishina H; Kakefuda Y; Wang Z; Noguchi Y; Aonuma K
    J Cardiol; 2012 Oct; 60(4):252-6. PubMed ID: 22835733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker.
    Takahata T; Yasui-Furukori N; Sakamoto J; Suto K; Suto T; Tateishi T; Munakata A
    Drugs R D; 2005; 6(6):385-94. PubMed ID: 16274261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of landiolol hydrochloride after off-pump coronary artery bypass.
    Maisawa K; Yamazaki K; Ishitoya H; Shimamura Y
    Asian Cardiovasc Thorac Ann; 2013 Apr; 21(2):170-5. PubMed ID: 24532615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male volunteers.
    Murakami M; Furuie H; Matsuguma K; Wanibuchi A; Kikawa S; Irie S
    Drug Metab Pharmacokinet; 2005 Oct; 20(5):337-44. PubMed ID: 16272751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese subjects.
    Wang M; Zhang Q; Hua W; Zhou W; Huang M; Wang H
    Drug Res (Stuttg); 2014 Mar; 64(3):141-5. PubMed ID: 24002929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery.
    Nishi H; Sakaguchi T; Miyagawa S; Yoshikawa Y; Fukushima S; Saito S; Ueno T; Kuratani T; Sawa Y
    Heart Vessels; 2013 Jul; 28(4):490-6. PubMed ID: 22661097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost minimization analysis of beta-blocker at the time of CT imaging for suspected of coronary heart disease in Japan.
    Igarashi A; Fujito K; Hirano M; Fukuda T
    J Med Econ; 2014 Feb; 17(2):142-7. PubMed ID: 24351028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of landiolol hydrochloride, a new beta-blocker, in coronary computed tomography angiography.
    Isobe S; Sato K; Sugiura K; Mimura T; Kobayashi M; Meno C; Kato M; Ishii H; Murohara T
    Int J Cardiol; 2010 Mar; 139(2):196-8. PubMed ID: 18703245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
    Kakihana Y; Nishida O; Taniguchi T; Okajima M; Morimatsu H; Ogura H; Yamada Y; Nagano T; Morishima E; Matsuda N;
    Lancet Respir Med; 2020 Sep; 8(9):863-872. PubMed ID: 32243865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).
    Sakamoto A; Kitakaze M; Takamoto S; Namiki A; Kasanuki H; Hosoda S;
    Circ J; 2012; 76(5):1097-101. PubMed ID: 22361918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Hanada K; Higuma T; Nishizaki F; Sukekawa T; Yokota T; Yamada M; Saito S; Kushibiki M; Oikawa K; Abe N; Tomita H; Osanai T; Okumura K
    Circ J; 2012; 76(2):439-45. PubMed ID: 22156314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Landiolol Hydrochloride on Hemodynamics in a Histamine-Induced Shock Model.
    Hirano M; Okamura T; Nagano T; Nonaka S; Shiroya T
    Drugs R D; 2021 Sep; 21(3):321-329. PubMed ID: 34128200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction.
    Ito N; Tashiro T; Morishige N; Nishimi M; Hayashida Y; Minematsu N; Kuwahara G; Sukehiro Y; Teratani H
    Heart Surg Forum; 2012 Aug; 15(4):E189-94. PubMed ID: 22917822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.